Lit-Control® de Devicare, la solución médica para prevenir y tratar las enfermedades urológicas recurrentes que representan la segunda causa de consultas de atención primaria1, se vende desde hace unas semanas en Francia. La novedad que presenta Lit-Control® es que se basa en el autocontrol monitorizado del pH urinario y empodera al paciente a gestionar su salud. Para ello, se proporciona…
Devicare and nine leading hospitals in urology have started the pioneering international "Double J" study to evaluate the combined use of a medical device and a nutraceutical in controlling urinary pH and inhibiting crystallisation in order to prevent the calcification of double J stent catheters and reduce the number of associated complications.
The prestigious urologists Manoj Monga of the Cleveland Clinic and Olivier Traxer of the Sorbonne and Pierre and Marie Curie University are organising the first The Talents (The Trans-Atlantic Leaders in Endourological Technologies) symposium, from 5 to 7 April in Paris, in order to build bridges between young European and North American leaders in the field of endourology.
The 33rd European Urology Congress (EAU 2018) closed its doors yesterday in Copenhagen with excellent figures: 15,000 urologists, 160 companies and 2,000 business representatives. Devicare has been present in the exhibition area together with one of its international partners presenting Lit-Control®, the first medical solution which allows recurrent urinary diseases to be effectively addressed with an innovative solution enabling patients to check their own urinary pH with remote monitoring.
Devicare has obtained the patent in Spain for a new electrochemical ion sensor, which is the most advanced of its type on the market, improving the features of the Lit-Control pH Meter® medical device for self-monitoring chronic urological diseases (lithiasis, infections, overactive bladder, calcification of urinary catheters, etc.). Specifically, the sensor incorporates a reference electrode that prevents it from drying after its use.
Devicare has obtained the patent in Spain for a new electrochemical ion sensor, which is the most advanced of its type on the market, improving the features of the Lit-Control pH Meter® medical device for self-monitoring chronic urological diseases (lithiasis, infections, overactive bladder, calcification of urinary catheters, etc.). Specifically, the sensor incorporates a reference electrode that prevents it from drying after its use.
LELR-AEU 2018 Meeting report Advances in the treatment and medical management of lithiasis, which affects 15% of Spain’s population and is increasing considerably, namely renal lithiasis, were the focus of the 28th National Meeting of the Groups of Lithiasis, Endourology, Laparoscopy and Robotics organized by the Spanish Association of Urology on January 25 and 26 in Cordoba.
Devicare has signed a participative loan worth 2 million Euros from the Innova Global line by Avançsa, assigned to the Business and Expertise Department, with the option to convert the investment into Series A stock in the mid-term. With this new economic injection, Devicare will continue the strategic development and validation plan of new medical solutions under the Remote Patient Monitoring concept...
Devicare has been one of the companies invited to the Lessons Learned held by the CataloniaBio and Biocat business association on 29 November in Barcelona to explain its business strategy and the lessons it has learned since it was founded in 2012. The debate centred on the convergence between the biopharmaceutical and MedTech sectors to contribute innovative and effective solutions to the world's most prominent diseases.
The Cerdanyola Empresarial gala took place yesterday in the Hotel of the Autonomous University of Barcelona, where Devicare collected the Prize for Research and innovation 2017 for its work in developing medical devices and solutions and remote patient monitoring. Rosendo Garganta, founder and CEO of Devicare, received the award from the president of the Entrepreneurs Association Lluís Sisquella.
Board Member and Private Investor in different biotech start-ups.
Former President of Medical Devices Committee at Catalonia Association of Biotech Companies.
Master in Business Administration.
Master in International Business.
Master in Entrepreneurship & Innovation.
BSc. Industrial Engineering.
BSc. Electronic Engineering.
+10 years of experience in Business Development in MD companies.
